Tocilizumab: a review of its use in the management of rheumatoid arthritis

V Oldfield, S Dhillon, GL Plosker - Drugs, 2009 - Springer
Summary Abstract Tocilizumab (RoActemra® or Actemra®) is a recombinant humanized
monoclonal antibody that acts as an interleukin (IL)-6 receptor antagonist. Intravenous …

Clinical pharmacology of gold

WF Kean, IRL Kean - Inflammopharmacology, 2008 - Springer
Since the dawn of civilization, elemental gold and gold compounds have been revered and
utilized by Shamen and medical practitioners alike for many varied pathological problems. In …

The use of TNF-α blocking agents in rheumatoid arthritis: an update

É Toussirot, D Wendling - Expert opinion on pharmacotherapy, 2007 - Taylor & Francis
TNF-α has been found to play a pivotal role in the pathogenic mechanisms of rheumatoid
arthritis (RA). Drugs targeting TNF-α have been developed to neutralise the deleterious …

[HTML][HTML] Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results

DC Titton, IG Silveira, P Louzada-Junior… - Revista Brasileira de …, 2011 - SciELO Brasil
OBJETIVOS: O presente estudo teve por objetivo descrever o processo de implementação
de um registro nacional em um país em desenvolvimento (Brasil) e relatar os principais …

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy

C Deighton, K Hyrich, T Ding, J Ledingham… - …, 2010 - academic.oup.com
Chris Deighton1, Kimme Hyrich2, Tina Ding1, Jo Ledingham3, Mark Lunt2, Raashid
Luqmani4, Patrick Kiely5, Marwan Bukhari6, Rikki Abernethy7, Andrew Ostor8, Ailsa …

The effects of rheumatoid arthritis on labor force participation, work performance, and healthcare costs in two workplace samples

RC Kessler, JR Maclean, M Petukhova… - … of occupational and …, 2008 - journals.lww.com
Objective: To assess the workplace costs of rheumatoid arthritis (RA) from the employer
perspective. Method: Samples included 4485 manufacturing firm (MF) employees (109 with …

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe

P Emery, R Van Vollenhoven, M Ostergaard… - Annals of the …, 2009 - ard.bmj.com
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease. In the majority of
patients the course is progressive and leads to destruction of joints, functional disability …

Development of quality indicators for monitoring of the disease course in rheumatoid arthritis

LTC Van Hulst, J Fransen, AA den Broeder… - Annals of the …, 2009 - ard.bmj.com
Objectives: To suppress rheumatoid arthritis (RA) patients' disease activity, it should be
periodically measured and patients should be treated on the basis of the disease activity …

Development and validation of a patient‐based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice

EH Choy, B Khoshaba, D Cooper… - Arthritis Care & …, 2008 - Wiley Online Library
Objective Assessor‐based disease activity measures such as the Disease Activity Score in
28 joints (DAS28), although widely used in rheumatoid arthritis (RA), have high …

Anti-tumor necrosis factor therapy and influenza: keeping it in perspective

M Shale, M Czub, GG Kaplan… - Therapeutic …, 2010 - journals.sagepub.com
The association of opportunistic infections in the context of anti-tumor necrosis factor (TNF)
antibody therapies have attracted widespread attention. The recent H1N1 influenza …